Analysis of cerebrospinal fluid cytokines and growth factors in multiple sclerosis patients with and without chronic headaches

Hikaru Doi, Takuya Matsushita, Noriko Isobe, Takahisa Tateishi, Jun ichi Kira

Research output: Contribution to journalArticle

Abstract

Background: We previously reported that, in Japanese patients with multiple sclerosis (MS), the frequency of chronic headaches was signifi cantly higher after administration of interferon beta (IFNβ). However, the mechanisms underlying IFNβ-related chronic headaches were unknown. Objective: To clarify the mechanisms underlying IFNβ-induced chronic headaches in MS patients by analyzing cytokine levels in cerebrospinal fluid (CSF). Methods: We measured the levels of 27 CSF cytokines and growth factors using a fluorescent bead-based immunoassay, during a headache-free period, in 34 MS patients enrolled in our previous survey on chronic headaches. Results: There were no signifi cant differences in CSF cytokine levels between the 21 MS patients with chronic headaches and the 13 without chronic headaches. Among the 14 patients receiving IFNβ therapy, the 5 patients with chronic headaches showed signifi cantly lower levels of interleukin (IL) 15, IL17 and chemokine (C-C motif) ligand 2 (CCL2) (also known as monocyte chemoattractant protein 1; MCP1) compared with the 9 patients without chronic headaches (P < 0.05). Conclusions: The present survey revealed that in MS, chronic headache sufferers on IFNβ therapy had decreased levels of IL15, IL17 and CCL2 in CSF. This suggests that chronic headaches may tend to develop in good responders to IFNβ.

Original languageEnglish
Pages (from-to)65-70
Number of pages6
JournalNeurology Asia
Volume16
Issue number1
Publication statusPublished - Mar 1 2011

Fingerprint

Headache Disorders
Multiple Sclerosis
Cerebrospinal Fluid
Intercellular Signaling Peptides and Proteins
Cytokines
Interferon-beta
Interleukin-15
Chemokine CCL2
Immunoassay
Headache
Ligands

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Analysis of cerebrospinal fluid cytokines and growth factors in multiple sclerosis patients with and without chronic headaches. / Doi, Hikaru; Matsushita, Takuya; Isobe, Noriko; Tateishi, Takahisa; Kira, Jun ichi.

In: Neurology Asia, Vol. 16, No. 1, 01.03.2011, p. 65-70.

Research output: Contribution to journalArticle

@article{0bc7dffa99c04d84a458ad4f5826e032,
title = "Analysis of cerebrospinal fluid cytokines and growth factors in multiple sclerosis patients with and without chronic headaches",
abstract = "Background: We previously reported that, in Japanese patients with multiple sclerosis (MS), the frequency of chronic headaches was signifi cantly higher after administration of interferon beta (IFNβ). However, the mechanisms underlying IFNβ-related chronic headaches were unknown. Objective: To clarify the mechanisms underlying IFNβ-induced chronic headaches in MS patients by analyzing cytokine levels in cerebrospinal fluid (CSF). Methods: We measured the levels of 27 CSF cytokines and growth factors using a fluorescent bead-based immunoassay, during a headache-free period, in 34 MS patients enrolled in our previous survey on chronic headaches. Results: There were no signifi cant differences in CSF cytokine levels between the 21 MS patients with chronic headaches and the 13 without chronic headaches. Among the 14 patients receiving IFNβ therapy, the 5 patients with chronic headaches showed signifi cantly lower levels of interleukin (IL) 15, IL17 and chemokine (C-C motif) ligand 2 (CCL2) (also known as monocyte chemoattractant protein 1; MCP1) compared with the 9 patients without chronic headaches (P < 0.05). Conclusions: The present survey revealed that in MS, chronic headache sufferers on IFNβ therapy had decreased levels of IL15, IL17 and CCL2 in CSF. This suggests that chronic headaches may tend to develop in good responders to IFNβ.",
author = "Hikaru Doi and Takuya Matsushita and Noriko Isobe and Takahisa Tateishi and Kira, {Jun ichi}",
year = "2011",
month = "3",
day = "1",
language = "English",
volume = "16",
pages = "65--70",
journal = "Neurology Asia",
issn = "1823-6138",
publisher = "ASEAN Neurological Association",
number = "1",

}

TY - JOUR

T1 - Analysis of cerebrospinal fluid cytokines and growth factors in multiple sclerosis patients with and without chronic headaches

AU - Doi, Hikaru

AU - Matsushita, Takuya

AU - Isobe, Noriko

AU - Tateishi, Takahisa

AU - Kira, Jun ichi

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background: We previously reported that, in Japanese patients with multiple sclerosis (MS), the frequency of chronic headaches was signifi cantly higher after administration of interferon beta (IFNβ). However, the mechanisms underlying IFNβ-related chronic headaches were unknown. Objective: To clarify the mechanisms underlying IFNβ-induced chronic headaches in MS patients by analyzing cytokine levels in cerebrospinal fluid (CSF). Methods: We measured the levels of 27 CSF cytokines and growth factors using a fluorescent bead-based immunoassay, during a headache-free period, in 34 MS patients enrolled in our previous survey on chronic headaches. Results: There were no signifi cant differences in CSF cytokine levels between the 21 MS patients with chronic headaches and the 13 without chronic headaches. Among the 14 patients receiving IFNβ therapy, the 5 patients with chronic headaches showed signifi cantly lower levels of interleukin (IL) 15, IL17 and chemokine (C-C motif) ligand 2 (CCL2) (also known as monocyte chemoattractant protein 1; MCP1) compared with the 9 patients without chronic headaches (P < 0.05). Conclusions: The present survey revealed that in MS, chronic headache sufferers on IFNβ therapy had decreased levels of IL15, IL17 and CCL2 in CSF. This suggests that chronic headaches may tend to develop in good responders to IFNβ.

AB - Background: We previously reported that, in Japanese patients with multiple sclerosis (MS), the frequency of chronic headaches was signifi cantly higher after administration of interferon beta (IFNβ). However, the mechanisms underlying IFNβ-related chronic headaches were unknown. Objective: To clarify the mechanisms underlying IFNβ-induced chronic headaches in MS patients by analyzing cytokine levels in cerebrospinal fluid (CSF). Methods: We measured the levels of 27 CSF cytokines and growth factors using a fluorescent bead-based immunoassay, during a headache-free period, in 34 MS patients enrolled in our previous survey on chronic headaches. Results: There were no signifi cant differences in CSF cytokine levels between the 21 MS patients with chronic headaches and the 13 without chronic headaches. Among the 14 patients receiving IFNβ therapy, the 5 patients with chronic headaches showed signifi cantly lower levels of interleukin (IL) 15, IL17 and chemokine (C-C motif) ligand 2 (CCL2) (also known as monocyte chemoattractant protein 1; MCP1) compared with the 9 patients without chronic headaches (P < 0.05). Conclusions: The present survey revealed that in MS, chronic headache sufferers on IFNβ therapy had decreased levels of IL15, IL17 and CCL2 in CSF. This suggests that chronic headaches may tend to develop in good responders to IFNβ.

UR - http://www.scopus.com/inward/record.url?scp=79954520107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954520107&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79954520107

VL - 16

SP - 65

EP - 70

JO - Neurology Asia

JF - Neurology Asia

SN - 1823-6138

IS - 1

ER -